4-nitro-3-phenylphenol | 21419-75-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-nitro-3-phenylphenol
• CAS: 21419-75-0
• 化学式: C₁₂H₉NO₃
• 分子量: 215.208
• InChiKey: LHJUVPXOXCFLCH-UHFFFAOYSA-N

物化性质

• 熔点：
  57-58 °C(Solv: benzene (71-43-2))
• 沸点：
  413.4±38.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-nitro-3-phenylphenol 在 四氯化碳 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 [6-nitro-1,1'-biphenyl-3-yl] dihydrogen phosphate
  参考文献：
  名称：

  Utilization of Nitrophenylphosphates and Oxime-Based Ligation for the Development of Nanomolar Affinity Inhibitors of the Yersinia pestis Outer Protein H (YopH) Phosphatase

  摘要：

  Our current study reports the first K(M) optimization of a library of nitrophenylphosphate-containing substrates for generating an inhibitor lead against the Yersinia pestis outer protein phosphatase (YopH). A high activity substrate identified by this method (K(M) = 80 mu M) was converted from a subs trate into an inhibitor by replacement of its phosphate group with difluoromethylphosphonic acid, and by attachment of an aminooxy handle for further structural optimization by mime ligation. A cocrystal structure of this aminooxy-containing platform in complex with YopH allowed the identification of a conserved water molecule proximal to the aminooxy group that was subsequenly employed for the design of furanyl-based oxime derivatives. By this process, a potent (IC(50) = 190 nM) and nonpromiscuous inhibitor was developed with good YopH selectivity relative to a panel of phosphatases. The inhibitor showed significant inhibition Of intracellular Y pestis replication at a noncytotoxic concentration. The current work presents general approaches to PTP inhibitor development that may be useful beyond YopH.

  DOI：

  10.1021/jm200022g
• 作为产物：
  描述：

  苯甲醛 在 ammonium acetate 、 碘 作用下， 以 溶剂黄146 、 二甲基亚砜 、 甲苯 为溶剂， 反应 50.0h， 生成 4-nitro-3-phenylphenol
  参考文献：
  名称：

  通过多官能化的环己酮从β-硝基苯乙烯一锅无金属地合成3-芳基-4-硝基苯酚

  摘要：

  β-硝基苯乙烯与Danishefsky的二烯进行Diels-Alder反应，得​​到环己烯以及相应的水解产物3-芳基-5-甲氧基-4-硝基环己酮。当反应在水的存在下进行时，环己烯被有效地水解成环己酮。随后通过将环己酮与催化量的碘在二甲基亚砜中加热来进行芳构化，得到3-芳基-4-硝基苯酚。硝基苯乙烯与Danishefsky的二烯的反应可以在一个罐中进行，以直接提供相应的硝基酚。此外，可以将杂芳基，例如噻吩基引入到硝基酚骨架中。

  DOI：

  10.3762/bjoc.16.150

文献信息

• Design, synthesis and structure–activity relationships of novel benzoxazolone derivatives as 18kDa translocator protein (TSPO) ligands
  作者：Takayuki Fukaya、Toru Kodo、Takeo Ishiyama、Hiroyoshi Kakuyama、Hiroyuki Nishikawa、Satoko Baba、Shuji Masumoto

  DOI：10.1016/j.bmc.2012.07.023

  日期：2012.9

  Selective 18 kDa translocator protein (TSPO) ligands are expected to be therapeutic agents with a wide spectrum of action on psychiatric disorders and fewer side effects. We designed novel benzoxazolone derivatives and examined the structure–activity relationship (SAR) of a series of compounds with various substituents at the amide part and C-5 position. Although a number of the synthesized compounds

  选择性的18 kDa转运蛋白（TSPO）配体有望成为对精神疾病具有广泛作用且副作用较少的治疗剂。我们设计了新颖的苯并恶唑酮衍生物，并研究了在酰胺部分和C-5位置具有多个取代基的一系列化合物的结构-活性关系（SAR）。尽管许多合成的化合物显示出高的TSPO结合亲和力，但这些化合物的药物样性质较差。这些化合物的药代动力学特性的进一步优化导致发现化合物74，该化合物在大鼠Vogel冲突模型中表现出抗焦虑作用。
• Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds
  申请人：Niculescu-Duvaz Dan

  公开号：US20070287838A1

  公开（公告）日：2007-12-13

  The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is independently —O— or —NR N1 —; R N1 , if present, is independently —H or a substituent; R N2 is independently —H or a substituent; Y is independently —CH═ or —N═; Q is independently —(CH 2 ) j -M-(CH 2 ) k — wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently —O—, —S—, —NH—, —NMe—, or —CH 2 —; each of R P1 , R P2 , R P3 , and R P4 is independently —H or a substituent; and additionally R P1 and R P2 taken together may be —CH═CH—CH═CH—; L is independently: a linker group formed by a chain of 2, 3, or 4 linker moieties; each linker moiety is independently —CH 2 —, —NR N —, —C(═X)—, or —S(═O) 2 —; exactly one linker moiety is —NR N —, or: exactly two linker moieties are —NR N —; exactly one linker moiety is —C(═X)—, and no linker moiety is —S(═O) 2 —; or: exactly one linker moiety is —S(═O) 2 —, and no linker moiety is —C(═X)—; no two adjacent linker moieties are —NR N —; X is independently ═O or ═S; each R N is independently —H or a substituent; A is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明涉及某些咪唑并[4,5-b]吡啶-2-酮和噁唑并[4,5-b]吡啶-2-酮化合物及其类似物，其中包括抑制RAF（例如B-RAF）活性、抑制细胞增殖、治疗癌症等功能，更具体地，涉及式（I）的化合物：其中：J独立地是—O—或—NRN1—；RN1，如果存在，独立地是—H或取代基；RN2独立地是—H或取代基；Y独立地是—CH═或—N═；Q独立地是—（CH2）j-M-（CH2）k—，其中：j独立地是0、1或2；k独立地是0、1或2；j+k为0、1或2；M独立地是—O—、—S—、—NH—、—NMe—或—CH2—；RP1、RP2、RP3和RP4中的每一个独立地是—H或取代基；并且RP1和RP2一起可以是—CH═CH—CH═CH—；L独立地是：由2、3或4个连接基成的连接基团；每个连接基独立地是—CH2—、—NRN—、—C（═X）—或—S（═O）2—；恰好一个连接基是—NRN—，或：恰好两个连接基是—NRN—；恰好一个连接基是—C（═X）—，且没有连接基是—S（═O）2—；或：恰好一个连接基是—S（═O）2—，且没有连接基是—C（═X）—；没有两个相邻的连接基是—NRN—；X独立地是═O或═S；每个RN独立地是—H或取代基；A独立地是：C6-14碳基芳基、C5-14杂环芳基、C3-12环烷基、C3-12杂环基；并且独立地是未取代或取代的；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、N-氧化物、化学保护形式和前药。本发明还涉及包含这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论在体内还是体外，用于抑制RAF（例如B-RAF）活性、抑制受体酪氨酸激酶（RTK）活性、抑制细胞增殖，并用于治疗由于抑制RAF、RTK等而改善的疾病和病况，如增殖性疾病，如癌症（例如结肠癌、黑色素瘤）等。
• Nitration of 3-Hydroxybiphenyl¹
  作者：J. C. Colbert、Daniel W. Fox、Charles Matuszak

  DOI：10.1021/ja01614a026

  日期：1955.5
• Derivatives of the Hydroxydiphenyls. III. 4-Nitro-3-hydroxydiphenyl
  作者：J. C. Colbert、Wyman Meigs、R. L. Jenkins

  DOI：10.1021/ja01285a048

  日期：1937.6
• Exploring Structural Determinants of Bias among D4 Subtype-Selective Dopamine Receptor Agonists
  作者：Fabian Graßl、Leonard Bock、Álvaro Huete-Huerta González、Martin Schiller、Peter Gmeiner、Jörg König、Martin F. Fromm、Harald Hübner、Markus R. Heinrich

  DOI：10.1021/acs.jmedchem.3c00537

  日期：2023.7.27